Search

Drug developers place their bets on the ROR-1 antigen in the battle against solid tumors.

Counterfeit deterrents are not yet available in some regions. We speak with Advanco CEO Alf Goebel to find out why.

What does sustainability look like at Cytiva?

Biosimilars, Switzerland and more; we interview Anne Marie de Jonge-Schuermans from the Swiss Biotech Association.

Experts discuss the most exciting Alzheimer’s Disease treatment trends – and make bold predictions for the future

Join us as we discuss how the SteriSEQ can help uncover potential contamination, thereby mitigating the risk of product loss, production delays, and maintaining the integrity of the final product.

Following on from deaths attributed to contaminated medicines, here’s how the US Pharmacopeia is promoting testing for DEG and EG.

How to choose equipment for oligonucleotide processes and other valuable tips for optimization.

Here’s how paper is weighing down the future of advanced therapies.

Progress in Alzheimer’s Disease research, but a cure will take time. Delaying it and disseminating that research may buy scientists the time they need